Equities analysts expect Wave Life Sciences Ltd (NASDAQ:WVE) to announce ($1.09) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Five analysts have made estimates for Wave Life Sciences’ earnings. The highest EPS estimate is ($0.95) and the lowest is ($1.27). Wave Life Sciences reported earnings per share of ($0.94) in the same quarter last year, which suggests a negative year-over-year growth rate of 16%. The company is scheduled to report its next earnings results on Thursday, November 8th.
According to Zacks, analysts expect that Wave Life Sciences will report full year earnings of ($4.62) per share for the current year, with EPS estimates ranging from ($5.14) to ($4.13). For the next year, analysts forecast that the business will post earnings of ($3.55) per share, with EPS estimates ranging from ($5.34) to ($2.00). Zacks’ EPS averages are an average based on a survey of analysts that follow Wave Life Sciences.
Wave Life Sciences (NASDAQ:WVE) last released its quarterly earnings data on Thursday, August 9th. The company reported ($1.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.88). The firm had revenue of $4.88 million for the quarter, compared to the consensus estimate of $7.38 million. Wave Life Sciences had a negative net margin of 1,473.26% and a negative return on equity of 92.00%.
A number of research firms have recently issued reports on WVE. Stifel Nicolaus began coverage on Wave Life Sciences in a research report on Monday, August 6th. They set a “buy” rating and a $56.00 price objective on the stock. BidaskClub cut Wave Life Sciences from a “strong-buy” rating to a “buy” rating in a research report on Thursday, June 21st. HC Wainwright set a $49.00 price objective on Wave Life Sciences and gave the company a “buy” rating in a research report on Friday. Mizuho set a $65.00 price objective on Wave Life Sciences and gave the company a “buy” rating in a research report on Thursday. Finally, ValuEngine upgraded Wave Life Sciences from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 2nd. One research analyst has rated the stock with a sell rating, five have given a buy rating and two have given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $58.40.
Shares of WVE traded up $5.00 on Friday, reaching $44.00. 152,412 shares of the stock traded hands, compared to its average volume of 136,479. The company has a debt-to-equity ratio of 0.04, a quick ratio of 7.24 and a current ratio of 7.24. Wave Life Sciences has a 12 month low of $16.05 and a 12 month high of $55.95.
In other Wave Life Sciences news, insider Chris Francis sold 48,992 shares of the company’s stock in a transaction on Friday, June 1st. The stock was sold at an average price of $46.75, for a total value of $2,290,376.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Paul Bolno sold 31,711 shares of the company’s stock in a transaction on Wednesday, May 30th. The shares were sold at an average price of $45.00, for a total value of $1,426,995.00. The disclosure for this sale can be found here. Insiders sold 105,199 shares of company stock worth $4,630,337 over the last quarter. Company insiders own 44.20% of the company’s stock.
Large investors have recently made changes to their positions in the business. Barclays PLC grew its holdings in shares of Wave Life Sciences by 11.2% during the first quarter. Barclays PLC now owns 16,201 shares of the company’s stock worth $650,000 after purchasing an additional 1,627 shares during the last quarter. UBS Group AG grew its holdings in shares of Wave Life Sciences by 26.0% during the first quarter. UBS Group AG now owns 8,356 shares of the company’s stock worth $335,000 after purchasing an additional 1,723 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Wave Life Sciences during the first quarter worth $120,000. Rhumbline Advisers grew its holdings in shares of Wave Life Sciences by 50.0% during the second quarter. Rhumbline Advisers now owns 16,116 shares of the company’s stock worth $616,000 after purchasing an additional 5,375 shares during the last quarter. Finally, California Public Employees Retirement System bought a new stake in shares of Wave Life Sciences during the first quarter worth $219,000. Hedge funds and other institutional investors own 80.78% of the company’s stock.
About Wave Life Sciences
Wave Life Sciences Ltd., a biotechnology company, designs, develops, and commercializes nucleic acid therapeutic candidates for genetically defined diseases by utilizing proprietary synthetic chemistry drug development platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.
Featured Article: Understanding Average Daily Trade Volume
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.